Quin Wills
About Quin Wills
Quin Wills serves as the Chief Scientific Officer and Co-Founder of Ochre Bio, where he has worked since 2019. He has a diverse academic and professional background in medicine, genomics, and biotechnology, with experience at prestigious institutions and companies across multiple countries.
Work at Ochre Bio
Quin Wills serves as the Chief Scientific Officer (CSO) and Co-founder of Ochre Bio, a company established in 2019. The organization focuses on developing advanced RNA therapies to treat liver diseases. It employs innovative techniques such as human organ ICUs and deep genomic phenotyping. Ochre Bio operates in multiple international locations, including Oxford, Taipei, and New York City, demonstrating a commitment to global biotechnology innovation.
Education and Expertise
Quin Wills has a strong educational background in medicine, genomics, and computational biology. He earned a Bachelor of Science with Honors in Human Genetics from the University of the Witwatersrand in 1999. He continued his studies at the University of Cambridge, obtaining an MPhil in Computational Biology in 2005. Wills also holds a Master of Science in Applied and Computational Mathematics and a Doctorate in Statistical Genomics, both from the University of Oxford. His expertise includes developing therapies that maintain whole human livers outside the body for research and treatment purposes.
Background
Prior to his role at Ochre Bio, Quin Wills held various positions in prominent research institutions. He worked as a Research Scientist at University College London from 2002 to 2003. He also served as a Career Development Fellow in Single Cell Genomics at the University of Oxford from 2014 to 2017. His experience includes a Postdoctoral Research Fellowship in Pharmacogenomics at Mayo Clinic from 2012 to 2013, and he was the Head of Cellular and Systems Genomics at Novo Nordisk Research Centre Oxford from 2017 to 2019.
Professional Experience
Quin Wills has co-founded and held leadership roles in several organizations. He was a Co-founder and CSO at SimuGen from 2005 to 2011, where he worked in London and Kuala Lumpur. His tenure at Novo Nordisk Research Centre Oxford lasted from 2017 to 2019, where he focused on cellular and systems genomics. His diverse professional background spans over two decades, contributing to advancements in drug development and biotechnology.